Evidence map›Paper›PMID 33842408›Full record

ArticleJournal of cancer prevention2021

Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

Mark Steven Miller, Peter J Allen, Powel H Brown, Andrew T Chan, Margie L Clapper, Roderick H Dashwood, Shadmehr Demehri, Mary L Disis, Raymond N DuBois, Robert J Glynn and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer prevention, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. TIME for Bugs: The Immune Microenvironment and Microbes in Precancer.Cancer prevention research (Philadelphia, Pa.) · 2023
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Mark Steven MillerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0003-1191-0977
Peter J AllenDivision of Surgical Oncology, Duke Cancer Institute, Durham, NC, USA.ORCID https://orcid.org/0000-0001-7912-9197
Powel H BrownDepartment of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-3398-163X
Andrew T ChanClinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.ORCID https://orcid.org/0000-0001-7284-6767
Margie L ClapperCancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0001-7712-5109
Roderick H DashwoodCenter for Epigenetics & Disease Prevention, Institute of Biosciences & Technology, Texas A&M Health Science Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-0351-4034
Shadmehr DemehriDepartment of Dermatology, Massachusetts General Hospital, Boston, MA, USA.ORCID https://orcid.org/0000-0002-7913-2641
Mary L DisisCancer Vaccine Institute, University of Washington School of Medicine, Seattle, WA, USA.ORCID https://orcid.org/0000-0001-7653-4648
Raymond N DuBoisDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.ORCID https://orcid.org/0000-0002-6385-7154
Robert J GlynnDivision of Preventive Medicine, Brigham & Women's Hospital, Boston, MA, USA.ORCID https://orcid.org/0000-0002-0697-8996
Thomas W KenslerPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-6676-261X
Seema A KhanDepartment of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID https://orcid.org/0000-0002-6307-2023
Bryon D JohnsonDepartment of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0001-7416-3396
Karen T LibyDepartment of Pharmacology & Toxicology, Michigan State University, East Lansing, Michigan, NY, USA.ORCID https://orcid.org/0000-0003-3317-3437
Steven M LipkinDivision of Gastroenterology and Hepatology, Weill Cornell University, New York, NY, USA.ORCID https://orcid.org/0000-0002-0603-9139
Susan R MalleryDepartment of Oral and Maxillofacial Pathology, College of Dentistry, Ohio State University, Columbus, OH, USA.ORCID https://orcid.org/0000-0003-3122-0244
Emmanuelle J MeuilletPHusis Therapeutics, San Diego, CA, USA.ORCID https://orcid.org/0000-0002-2242-0810
Richard B S RodenDepartment of Pathology, Cancer Prevention and Control Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-2506-0195
Robert E SchoenDivision of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-7153-2766
Zelton D SharpDepartment of Molecular Medicine, University of Texas Science Center at San Antonio, San Antonio, TX, USA.ORCID https://orcid.org/0000-0002-6580-5366
Haval ShirwanDepartment of Child Health and Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA.ORCID https://orcid.org/0000-0002-1657-9470
Jill M SiegfriedDepartment of Pharmacology, Masonic Cancer Center, University of Minnesota School of Medicine, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-0887-5448
Chinthalapally V RaoMedical Oncology Center for Cancer Prevention & Drug Development, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.ORCID https://orcid.org/0000-0002-5715-7979
Ming YouDepartment of Pharmacology and Toxicology, Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0002-9741-268X
Eduardo VilarDepartment of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0001-6404-3761
Eva SzaboLung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.ORCID https://orcid.org/0000-0003-3891-0942
Altaf MohammedChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0003-1058-6909

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI WARNER KING HUH, TZYY-CHOOU WU · 2003 to 2026
$53.5M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
Transplacental Chemoprevention of Lung Tumors and LymphomasP01CA090890 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DASHWOOD, RODERICK H · 2003 to 2014
$14.2M
Precision Prevention Research ProgramR35CA253185 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Andrew T Chan · 2020 to 2026
$6.9M
Targeting Nrf2 for Cancer ChemopreventionR35CA197222 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KENSLER, THOMAS W · 2015 to 2021
$6.7M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
Dietary HDAC Inhibitors in Colon Cancer PreventionR01CA122959 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DASHWOOD, RODERICK H · 2008 to 2023
$4.3M
Epithelium-derived alarmins role in breast cancer immunopreventionU01CA233097 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DEMEHRI, SHADMEHR · 2018 to 2022
$4.0M
Neoantigen Vaccination for Lynch Syndrome ImmunopreventionU01CA233056 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LIPKIN, STEVEN M, VILAR SANCHEZ, EDUARDO · 2018 to 2022
$3.8M
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung CancerR01CA223804 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, LI LILY, YOU, MING · 2018 to 2022
$3.3M
CLC NIH HHS 75N90019D00021NCI NIH HHS F31 CA213982NCI NIH HHS HHSN261201500018CNCI NIH HHS P01 CA090890NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA122959NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA193835NCI NIH HHS R01 CA202704NCI NIH HHS R01 CA211611NCI NIH HHS R01 CA213987NCI NIH HHS R01 CA217161NCI NIH HHS R01 CA219463NCI NIH HHS R01 CA223804NCI NIH HHS R01 CA226690NCI NIH HHS R01 CA227273NCI NIH HHS R01 CA233486NCI NIH HHS R01 CA235677NCI NIH HHS R01 CA237067NCI NIH HHS R01 CA258757NCI NIH HHS R35 CA197222NCI NIH HHS R35 CA253185NCI NIH HHS R41 CA199956NCI NIH HHS U01 CA233056NCI NIH HHS U01 CA233097NIA NIH HHS U19 AG062682NIH HHS DP5 OD021353ORFDO NIH HHS 75N99019D00021
6 · The paper itself

Abstract

The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.

Indexed as

Cancer vaccinesChemopreventionClinical trials as topicImmunoprevention

Identifiers

PMID33842408
PMCPMC8020174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.